News Releases

Printer friendly version

Protox Therapeutics conference call notification

Wednesday, March 8, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V:  PRX) will hold an investor conference call to discuss the progress of the company’s prostate cancer and benign prostatic hyperplasia (BPH) programs on Monday, March 13th at 1:00p.m. PST (4:00p.m. EST). To participate on the call, please dial 604-899-1159 or 1-888-458-1598  before 1:00 p.m. PST (access code 27319). A replay of the call will be available via the Internet at www.protoxtherapeutics.com and also via telephone at 1-877-653-0545 (access code 310769).

About Protox Therapeutics
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. The company’s PORxin™ platform is based on engineered proaerolysin, a naturally-occurring pore-forming protoxin. Product candidates generated using the PORxin™ platform are inactive prodrugs that are activated at the tumor site into potent toxins by cancer specific proteases, thereby causing cancer cell death.  PRX302, the company’s lead product candidate for localized prostate cancer and benign prostatic hyperplasia, is a first-in-class pore-forming targeted toxin for cancer therapy.

Link to the webcast replay of the conference call Monday, March 13, 2006 at 1:00PM PST

For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Tel: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com